Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Accuronix Therapeutics Logo
Accuronix Therapeutics Growth Score
38
CB Rank
288454
Heat Score
21
Accuronix Therapeutics is a biotech company that develops drug targeting technology to resolve issues in cancer therapy.
Founded
obfuscation
PrivateSeed St Louis, Missouri, United States1-10 accuronix.com/
Biotechnology
Health Care
Therapeutics
Overview

Accuronix Therapeutics
Total Funding
obfuscation
Growth Score
38
Heat Score
21

Total Funding
obfuscation
obfuscation
Seed raised
obfuscation
Growth Score38
-1 pts
in past quarter
Heat Score 21
6 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Accuronix Therapeutics

CB Rank
288454
Accuronix Therapeutics is a biotech company that develops drug targeting technology to resolve issues in cancer therapy.
Founded
obfuscation
PrivateSeed St Louis, Missouri, United States1-10 accuronix.com/
Biotechnology
Health Care
Therapeutics

Funding Rounds

Seed
OBF
in
obfuscation

Key People

Details

Legal Name Accuronix Therapeutics Inc
Operating Status Active
Company Type For Profit
Founders  Robert Mach, William Hawkins
About the Company
We are applying a novel drug-targeting technology to some of the most difficult problems in cancer therapy.
Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

σ-2 Molecularly Targeted Drug Conjugates
Accuronix Therapeutics develops drug conjugates targeting the σ-2 receptor, overexpressed in most human cancers, for selective delivery of therapeutic agents.
ACXT-3102
A novel small molecule drug conjugate targeting the σ-2 receptor for treating pancreatic adenocarcinoma and other rare tumors, promoting cancer cell death through apoptosis and ferroptosis.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 1
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Seed Round - Accuronix Therapeutics Logo
Seed Round - Accuronix Therapeutics
2
obfuscation
— Seed
obfuscation
Seed Round - Accuronix Therapeutics Logo
Seed Round - Accuronix Therapeutics
2
obfuscation
— Seed
obfuscation
Seed Round - Accuronix Therapeutics Logo
Seed Round - Accuronix Therapeutics
2
obfuscation
— Seed
obfuscation
Seed Round - Accuronix Therapeutics Logo
Seed Round - Accuronix Therapeutics
2
obfuscation
— Seed
obfuscation
Seed Round - Accuronix Therapeutics Logo
Seed Round - Accuronix Therapeutics
2
obfuscation
— Seed

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 1
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Seed Round - Accuronix Therapeutics Logo
Seed Round - Accuronix Therapeutics
2
obfuscation
— Seed
obfuscation
Seed Round - Accuronix Therapeutics Logo
Seed Round - Accuronix Therapeutics
2
obfuscation
— Seed
obfuscation
Seed Round - Accuronix Therapeutics Logo
Seed Round - Accuronix Therapeutics
2
obfuscation
— Seed
obfuscation
Seed Round - Accuronix Therapeutics Logo
Seed Round - Accuronix Therapeutics
2
obfuscation
— Seed
obfuscation
Seed Round - Accuronix Therapeutics Logo
Seed Round - Accuronix Therapeutics
2
obfuscation
— Seed

Investors

Market Intelligence
People
View Profiles & Contacts
Headcount 1-10 Employee Profiles 4 Contacts 1

Employee Profiles

News

News and Press

News•Apr 15, 2016
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

IT Spend

$69.1KThis year, Accuronix Therapeutics is projected to spend $69.1K on IT, according to Aberdeen.

Active Website Tech Count

4Accuronix Therapeutics is actively using 4 technologies for its website, according to BuiltWith. These include Common Crawl, CommonCrawl Top 50m, and  Euro.
Sub-Organizations
Frequently Asked Questions

Where is Accuronix Therapeutics's headquarters? Accuronix Therapeutics is located in St Louis, Missouri, United States.Who invested in Accuronix Therapeutics? Accuronix Therapeutics has 2 investors including Missouri Technology Corporation and  BioGenerator.When was the last funding round for Accuronix Therapeutics? Accuronix Therapeutics closed its last funding round on
obfuscation
from a Seed round.Who are Accuronix Therapeutics's competitors? Alternatives and possible competitors to Accuronix Therapeutics may include Debiopharm Group, Mersana Therapeutics, and  Eisai US.How much funding has Accuronix Therapeutics raised to date? Accuronix Therapeutics has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(fe3140e 1)
|